WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that Richard Chin, M.D., President and CEO, will present a corporate update to investors in Stockholm, Sweden, on December 11, 2007.
